The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis

被引：10

作者：

Fleischmann, Roy ^{[1
]}

机构：

[1] Metroplex Clin Res Ctr, Dallas, TX 75231 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2010年 / 10卷 / 05期

关键词：

anti-TNF therapy; biological therapies; certolizumab; rheumatoid arthritis; ANTITUMOR-NECROSIS-FACTOR; DIFFERENT TREATMENT STRATEGIES; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; TREATMENT OUTCOMES; PLUS METHOTREXATE; MEASURING FATIGUE; WORK DISABILITY; JOINT DAMAGE; PHASE-III;

D O I：

10.1517/14712591003724688

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Importance of the field: The treatment of rheumatoid arthritis has changed dramatically over the past 25 years, first with the introduction of methotrexate and then the introduction of biologic therapy. These agents have provided patients with multiple treatment options to try to achieve disease remission. Unfortunately, no one single agent is fully effective in every patient; different patients respond to different therapies, even those with the same mechanism of action, in different ways. Another medication, such as certolizumab pegol, is a welcome addition to our treatment armamentarium of rheumatoid arthritis. Areas covered in this review: The basis of this review is all the peer-reviewed manuscripts found in PubMed and Medline searches from 1990 to 2009 and abstracts on certolizumab pegol presented at the American College of Rheumatology and European League Against Rheumatism within the past 5 years. What the reader will gain: This review should enable the reader to fully understand the benefit: risk ratio of certolizumab pegol in the treatment of rheumatoid arthritis. Take home message: Certolizumab pegol is an effective agent either in combination with methotrexate or as monotherapy in the treatment of rheumatoid arthritis with a safety profile similar to other approved TNF inhibitors.

引用

页码：773 / 786

页数：14

共 71 条

[1]

Socio-economic consequences of rheumatoid arthritis in the first years of the disease [J].

Albers, JMC ;

Kuper, HH ;

van Riel, PLCM ;

Prevoo, MLL ;

Van't Hof, MA ;

van Gestel, AM ;

Severens, JL .

RHEUMATOLOGY, 1999, 38 (05) :423-430

[2]

Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey [J].

Aletaha, D ;

Eberl, G ;

Nell, VPK ;

Machold, KP ;

Smolen, JS .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1269-1275

[3]

THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4]

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[5]

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease - Exploring a new mechanism of action [J].

Bourne, Tim ;

Fossati, Gianluca ;

Nesbitt, Andrew .

BIODRUGS, 2008, 22 (05) :331-337

[6]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[7]

Should rheumatoid arthritis be treated conservatively or aggressively? [J].

Breedveld, FC .

RHEUMATOLOGY, 2003, 42 :41-43

[8]

Therapeutic antibody fragments with prolonged in vivo half-lives [J].

Chapman, AP ;

Antoniw, P ;

Spitali, M ;

West, S ;

Stephens, S ;

King, DJ .

NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783

[9]

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].

Clair, EWS ;

van der Heijde, DMFM ;

Smolen, JS ;

Maini, RN ;

Bathon, JM ;

Emery, P ;

Keystone, E ;

Schiff, M ;

Kalden, JR ;

Wang, B ;

DeWoody, K ;

Weiss, R ;

Baker, D .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443

[10]

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

← 1 2 3 4 5 6 7 8 →